For most people, semaglutide (the active ingredient in Ozempic) has a well-established safety profile, but it comes with real side effects that range from common and manageable to rare and serious. The largest trial to date, SELECT, followed over 17,600 participants for four years and found no unexpected safety issues. Serious adverse events were actually slightly lower in the semaglutide group (33%) than in the placebo group (36%), driven largely by fewer cardiac problems.
That said, “safe” doesn’t mean “side-effect free.” Understanding what’s likely, what’s rare, and what disqualifies you from using the drug is the best way to make an informed decision.
Ozempic vs. Wegovy: A Key Distinction
Ozempic is FDA-approved for type 2 diabetes, not weight loss. The same molecule, semaglutide, is approved for weight management under the brand name Wegovy at a higher dose. When doctors prescribe Ozempic specifically for weight loss, they’re prescribing it off-label. This is legal and common, but it means the drug hasn’t gone through the FDA approval process specifically for that use at that dose. Wegovy has, and it’s also approved to reduce the risk of serious heart problems in adults with obesity or overweight.
Gastrointestinal Side Effects Are Very Common
The most frequent complaint, by far, is nausea. In clinical comparisons, about 53% of people taking semaglutide experienced nausea versus roughly 22% on placebo. Vomiting affected around 30% of users (compared to under 5% on placebo), and diarrhea hit about 35% versus 24% on placebo. These numbers are high enough that you should expect some GI discomfort, particularly in the first few months.
Most of these symptoms peak during the dose-escalation phase, which is the first 16 to 20 weeks when your dose is gradually increased. In the four-year SELECT trial, GI symptoms were the top reason people quit semaglutide, but the majority who pushed through the early weeks found the side effects became tolerable or resolved. Starting low and increasing slowly is the standard approach precisely because it reduces the intensity of these symptoms.
Stomach Paralysis: Rare but Real
Semaglutide works partly by slowing how fast your stomach empties, which helps you feel full longer. In a small number of people, this effect goes too far, leading to gastroparesis, a condition where the stomach struggles to move food into the small intestine at all. A University of British Columbia study found that GLP-1 drugs were associated with a 3.67 times higher risk of gastroparesis compared to other weight loss medications. Symptoms include persistent nausea, vomiting, bloating, and abdominal pain that don’t improve with time.
Researchers note that while gastroparesis remains rare on an individual level, the sheer number of people now using these drugs means hundreds of thousands could potentially be affected worldwide. If you develop vomiting or nausea that worsens rather than improves after the first few months, that’s worth flagging to your prescriber promptly.
Muscle Loss Is Higher Than Expected
Weight loss from any method involves losing some muscle along with fat. The general rule of thumb is that about one-quarter of weight lost comes from lean tissue. Semaglutide appears to exceed that. In the STEP-1 trial, participants lost an average of 15.3 kg (about 34 pounds), but 6.92 kg of that was lean mass. That means roughly 45% of the weight lost was muscle and other non-fat tissue, nearly double what’s typically expected.
This matters because muscle loss affects your metabolism, physical strength, bone support, and long-term ability to keep weight off. Resistance training and adequate protein intake are widely recommended to counteract this effect, though no large trial has formally tested how well those strategies work alongside semaglutide specifically. If you’re older or already have low muscle mass, this tradeoff deserves a serious conversation with your doctor.
Gallbladder Problems
Rapid weight loss from any cause increases the risk of gallstones, and semaglutide is no exception. The four-year SELECT trial confirmed that gallstone rates were higher in the semaglutide group than in the placebo group. Gallstones can be painless or can cause intense abdominal pain, particularly after eating fatty meals. Some cases require surgery to remove the gallbladder. This risk isn’t unique to semaglutide, but the significant weight loss the drug produces makes it a relevant concern.
Kidney Stress From Dehydration
Semaglutide doesn’t directly damage the kidneys in most cases, but the nausea and vomiting it causes can lead to dehydration, which in turn can trigger acute kidney injury. Post-marketing data shows that kidney problems with GLP-1 drugs are mostly tied to fluid loss from GI side effects, sometimes worsened by blood pressure medications that further affect fluid balance. The drug also appears to increase sodium excretion through the kidneys, which can compound the dehydration effect.
People over 45, those who weigh more than about 220 pounds, and anyone with existing kidney concerns appear to face higher risk. Staying well-hydrated is not just general wellness advice here; it’s a genuine protective measure. If you’re vomiting frequently and can’t keep fluids down, contact your prescriber rather than waiting it out.
Thyroid Cancer Concerns
Semaglutide carries a boxed warning (the FDA’s most serious label warning) about thyroid cancer risk. This stems from animal studies where rodents developed thyroid C-cell tumors at high doses. Whether this translates to humans has been an open question. A large Scandinavian study looking at real-world GLP-1 use found no significant increase in any thyroid cancer subtype, including medullary thyroid cancer, though the number of cases was small and the estimates for rarer subtypes were imprecise.
The drug is strictly off-limits if you or a close family member has a history of medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2, which causes tumors in multiple glands. Outside of those specific situations, the current human evidence has not confirmed the thyroid risk seen in animals.
Pancreatitis: Monitored but Not Confirmed
Inflammation of the pancreas has been a theoretical concern with GLP-1 drugs for years. The SELECT trial, the longest and largest semaglutide study to date, did not find an increased rate of pancreatitis in the semaglutide group. That’s reassuring, though individual case reports exist. Symptoms to watch for include severe, persistent abdominal pain that radiates to your back, especially if accompanied by vomiting.
What Four Years of Data Show
The SELECT trial provides the most complete long-term safety picture available. Over 208 weeks, participants on semaglutide lost an average of 10.2% of their body weight and 7.7 cm from their waistline, compared to 1.5% and 1.3 cm in the placebo group. Over half moved down at least one BMI category after two years, and 12% reached a healthy BMI, compared to just 1% on placebo.
On the safety side, no new or unexpected problems emerged over four years. The overall rate of serious adverse events was actually lower with semaglutide than with placebo, largely because the drug reduced cardiovascular events. The side effects that did cause people to stop were overwhelmingly gastrointestinal and concentrated in the early months. For people who tolerated the initial phase, the long-term safety signal was favorable.
Who Should Not Take It
Semaglutide is contraindicated if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. You should not combine it with other semaglutide-containing products or other GLP-1 drugs. People with a history of pancreatitis, severe kidney disease, or gastroparesis should discuss these conditions thoroughly before starting treatment, as the drug could worsen them. Kidney function testing before starting is recommended for people with risk factors like older age, obesity, or existing kidney concerns.